TY - JOUR
T1 - Early diagnosis of bladder cancer through the detection of urinary tyrosine-phosphorylated proteins
AU - Khadjavi, A.
AU - Mannu, F.
AU - Destefanis, P.
AU - Sacerdote, C.
AU - Battaglia, A.
AU - Allasia, M.
AU - Fontana, D.
AU - Frea, B.
AU - Polidoro, S.
AU - Fiorito, G.
AU - Matullo, G.
AU - Pantaleo, A.
AU - Notarpietro, A.
AU - Prato, M.
AU - Castagno, F.
AU - Vineis, P.
AU - Gontero, P.
AU - Giribaldi, G.
AU - Turrini, F.
N1 - Publisher Copyright:
© 2015 Cancer Research UK. All rights reserved.
PY - 2015/7/28
Y1 - 2015/7/28
N2 - Background: A noninvasive, highly sensitive and specific urine test is needed for bladder cancer (BC) diagnosis and surveillance in addition to the invasive cystoscopy. We previously described the diagnostic effectiveness of urinary tyrosine-phosphorylated proteins (UPY) and a new assay (UPY-A) for their measurement in a pilot study. The aim of this work was to evaluate the performances of the UPY-A using an independent cohort of 262 subjects.Methods: Urinary tyrosine-phosphorylated proteins were measured by UPY-A test. The area under ROC curve, cutoff, sensitivity, specificity and predictive values of UPY-A were determined. The association of UPY levels with tumour staging, grading, recurrence and progression risk was analysed by Kruskal-Wallis and Wilcoxon's test. To test the probability to be a case if positive at the UPY-A, a logistic test adjusted for possible confounding factor was used.Results: Results showed a significant difference of UPY levels between patients with BC vs healthy controls. For the best cutoff value, 261.26 Standard Units (SU), the sensitivity of the assay was 80.43% and the specificity was 78.82%. A statistically significant difference was found in the levels of UPY at different BC stages and grades between Ta and T1 and with different risk of recurrence and progression. A statistically significant increased risk for BC at UPY-A ≥261.26 SU was observed.Conclusions: The present study supplies important information on the diagnostic characteristics of UPY-A revealing remarkable performances for early stages and allowing its potential use for different applications encompassing the screening of high-risk subjects, primary diagnosis and posttreatment surveillance.
AB - Background: A noninvasive, highly sensitive and specific urine test is needed for bladder cancer (BC) diagnosis and surveillance in addition to the invasive cystoscopy. We previously described the diagnostic effectiveness of urinary tyrosine-phosphorylated proteins (UPY) and a new assay (UPY-A) for their measurement in a pilot study. The aim of this work was to evaluate the performances of the UPY-A using an independent cohort of 262 subjects.Methods: Urinary tyrosine-phosphorylated proteins were measured by UPY-A test. The area under ROC curve, cutoff, sensitivity, specificity and predictive values of UPY-A were determined. The association of UPY levels with tumour staging, grading, recurrence and progression risk was analysed by Kruskal-Wallis and Wilcoxon's test. To test the probability to be a case if positive at the UPY-A, a logistic test adjusted for possible confounding factor was used.Results: Results showed a significant difference of UPY levels between patients with BC vs healthy controls. For the best cutoff value, 261.26 Standard Units (SU), the sensitivity of the assay was 80.43% and the specificity was 78.82%. A statistically significant difference was found in the levels of UPY at different BC stages and grades between Ta and T1 and with different risk of recurrence and progression. A statistically significant increased risk for BC at UPY-A ≥261.26 SU was observed.Conclusions: The present study supplies important information on the diagnostic characteristics of UPY-A revealing remarkable performances for early stages and allowing its potential use for different applications encompassing the screening of high-risk subjects, primary diagnosis and posttreatment surveillance.
UR - http://www.scopus.com/inward/record.url?scp=84938417500&partnerID=8YFLogxK
U2 - 10.1038/bjc.2015.232
DO - 10.1038/bjc.2015.232
M3 - Article
SN - 0007-0920
VL - 113
SP - 469
EP - 475
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 3
ER -